These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11030020)

  • 1. Factors to consider in selecting an angiotensin-converting-enzyme inhibitor.
    Waugh WJ
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S26-30. PubMed ID: 11030020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using ACE inhibitors appropriately.
    Bicket DP
    Am Fam Physician; 2002 Aug; 66(3):461-8. PubMed ID: 12182524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
    Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulary management of ACE inhibitors.
    Gerbrandt KR; Yedinak KC
    Pharmacoeconomics; 1996 Dec; 10(6):594-613. PubMed ID: 10164060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors.
    Brown NJ; Vaughan DE
    Circulation; 1998 Apr; 97(14):1411-20. PubMed ID: 9577953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
    Pellizzer AM; Krum H
    Aust Fam Physician; 1996 Jul; 25(7):1067-9, 1072-3, 1076-7. PubMed ID: 8768273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
    Peters DC; Noble S; Plosker GL
    Drugs; 1998 Nov; 56(5):871-93. PubMed ID: 9829159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation.
    Chaturvedi N
    Lancet; 2000 Jan; 355(9200):246-7. PubMed ID: 10675066
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral angiotensin-converting-enzyme inhibitors.
    Verme-Gibboney C
    Am J Health Syst Pharm; 1997 Dec; 54(23):2689-703. PubMed ID: 9408513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.